PMID- 26089823
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150619
LR  - 20201226
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 6
DP  - 2015
TI  - Present and Future of Allogeneic Natural Killer Cell Therapy.
PG  - 286
LID - 10.3389/fimmu.2015.00286 [doi]
LID - 286
AB  - Natural killer (NK) cells are innate lymphocytes that are capable of eliminating 
      tumor cells and are therefore used for cancer therapy. Although many early 
      investigators used autologous NK cells, including lymphokine-activated killer 
      cells, the clinical efficacies were not satisfactory. Meanwhile, human leukocyte 
      antigen (HLA)-haploidentical hematopoietic stem cell transplantation revealed the 
      antitumor effect of allogeneic NK cells, and HLA-haploidentical, killer cell 
      immunoglobulin-like receptor ligand-mismatched allogeneic NK cells are currently 
      used for many protocols requiring NK cells. Moreover, allogeneic NK cells from 
      non-HLA-related healthy donors have been recently used in cancer therapy. The use 
      of allogeneic NK cells from non-HLA-related healthy donors allows the selection 
      of donor NK cells with higher flexibility and to prepare expanded, cryopreserved 
      NK cells for instant administration without delay for ex vivo expansion. In 
      cancer therapy with allogeneic NK cells, optimal matching of donors and 
      recipients is important to maximize the efficacy of the therapy. In this review, 
      we summarize the present state of allogeneic NK cell therapy and its future 
      directions.
FAU - Lim, Okjae
AU  - Lim O
AD  - Virology and Immunology Team, MOGAM Biotechnology Institute , Yongin , South 
      Korea.
FAU - Jung, Mi Young
AU  - Jung MY
AD  - Virology and Immunology Team, MOGAM Biotechnology Institute , Yongin , South 
      Korea.
FAU - Hwang, Yu Kyeong
AU  - Hwang YK
AD  - Cell Therapy Center, GreenCross LabCell , Yongin , South Korea.
FAU - Shin, Eui-Cheol
AU  - Shin EC
AD  - Laboratory of Immunology and Infectious Diseases, Graduate School of Medical 
      Science and Engineering, KAIST , Daejeon , South Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150603
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC4453480
OTO - NOTNLM
OT  - adoptive cell therapy
OT  - allogeneic
OT  - cancer immunotherapy
OT  - natural killer cells
OT  - non-HLA-related donor
EDAT- 2015/06/20 06:00
MHDA- 2015/06/20 06:01
PMCR- 2015/01/01
CRDT- 2015/06/20 06:00
PHST- 2015/03/31 00:00 [received]
PHST- 2015/05/18 00:00 [accepted]
PHST- 2015/06/20 06:00 [entrez]
PHST- 2015/06/20 06:00 [pubmed]
PHST- 2015/06/20 06:01 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2015.00286 [doi]
PST - epublish
SO  - Front Immunol. 2015 Jun 3;6:286. doi: 10.3389/fimmu.2015.00286. eCollection 2015.